Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11689424 | 0.86 | ALOX15 (0.47) | ALOX15ALDH1A1TSHRCYP2D6CYP2C19 | |
| SCHEMBL11868741 | 0.74 | ALOX15 (0.52) | ALOX15ALDH1A1TSHRSRCKDM4E | |
| SCHEMBL17131606 | 0.73 | ALOX15 (0.50) | ALOX15ALDH1A1TSHRSRCMETAP2 | |
| SCHEMBL873011 | 0.72 | ALOX15 (0.46) | ALOX15ALDH1A1TSHRCYP2D6CYP2C19 | |
| SCHEMBL27887115 | 0.71 | ALOX15 (0.44) | ALOX15ALDH1A1TSHRSRCUSP2 | |
| SCHEMBL19973165 | 0.70 | ALOX15 (0.45) | ALOX15ALDH1A1TSHRCYP2D6CYP2C19 | |
| SCHEMBL237275 | 0.69 | ALOX15 (0.47) | ALOX15ALDH1A1TSHRSRCUSP2 | |
| SCHEMBL12027362 | 0.69 | ALOX15 (0.47) | ALOX15ALDH1A1TSHRSRCKDM4E | |
| SCHEMBL214608 | 0.69 | — | — | |
| SCHEMBL9175546 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111690218-A | Environment-friendly rat-proof and termite-proof plastic insulated control cable | 李坤 | 2020-09-22 | — | — | CN | disclosed |
| US-20150266847-A1 | MACROCYCLIC TRIENE LACTONES HAVING UNCONJUGATED TRIENE STRUCTURE, ITS PRODUCTION METHOD AND ITS SYNTHETIC INTERMEDIATE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-09-24 | — | — | US | disclosed |
| US-9085545-B2 | Macrocyclic triene lactones having unconjugated triene structure, its production method and its synthetic intermediate | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-07-21 | — | — | US | disclosed |
| US-20140163099-A1 | ANTIMICROBIAL COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-06-12 | — | — | US | disclosed |
| EP-2725900-A1 | ANTIMICROBIAL COMPOSITION | Takasago International Corporation (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-20130324744-A1 | MACROCYCLIC TRIENE LACTONES HAVING UNCONJUGATED TRIENE STRUCTURE, ITS PRODUCTION METHOD AND ITS SYNTHETIC INTERMEDIATE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-12-05 | — | — | US | disclosed |
| US-20130005807-A1 | ANTIMICROBIAL COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-01-03 | — | — | US | disclosed |
| WO-2013002421-A1 | ANTIMICROBIAL COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-01-03 | — | — | WO | disclosed |
| WO-2012115285-A1 | MACROCYCLIC TRIENE LACTONES HAVING UNCONJUGATED TRIENE STRUCTURE, ITS PRODUCTION METHOD AND ITS SYNTHETIC INTERMEDIATE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-08-30 | — | — | WO | disclosed |
| US-7964637-B2 | Process for producing optically active theaspirane | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-06-21 | — | — | US | disclosed |
| US-20090270516-A1 | Process for Producing Optically Active Theaspirane | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324744-A1 | MACROCYCLIC TRIENE LACTONES HAVING UNCONJUGATED TRIENE STRUCTURE, ITS PRODUCTION METHOD AND ITS SYNTHETIC INTERMEDIATE | TAS2R13, TAS2R40, TAS2R14 | ALOX15 401/4885ALDH1A1 2177/4885TSHR 1887/4885 |
| US-20090270516-A1 | Process for Producing Optically Active Theaspirane | DHPS, ALDH7A1, FASN | ALOX15 389/4885ALDH1A1 38/4885TSHR 4388/4885 |
| US-20150266847-A1 | MACROCYCLIC TRIENE LACTONES HAVING UNCONJUGATED TRIENE STRUCTURE, ITS PRODUCTION METHOD AND ITS SYNTHETIC INTERMEDIATE | TAS2R13, TAS2R40, TAS2R14 | ALOX15 401/4885ALDH1A1 2177/4885TSHR 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.